Parenteral antithrombotic therapy during primary percutaneous coronary intervention

Federico Fortuni, Marco Ferlini, Sergio Leonardi

Research output: Contribution to journalReview articlepeer-review


Acute myocardial infarction (AMI) is a major cause of morbidity, mortality and disability worldwide. ST-segment elevation myocardial infarction (STEMI) accounts for 25-40% of AMI presentations. Arterial thrombosis due to atherosclerotic plaque rupture with formation of an occlusive thrombus is the main cause of STEMI. Platelets and coagulation factors are the two principal elements involved in this process. The main goal of STEMI treatment is the early reperfusion. Prompt primary percutaneous coronary intervention (pPCI) together with an appropriate antithrombotic therapy are the treatment of choice in this setting. In this chapter, we provide an overview of currently available parenteral antithrombotic therapies used in patients with STEMI undergoing pPCI.

Original languageEnglish
Pages (from-to)411-421
Number of pages11
JournalMinerva Cardioangiologica
Issue number4
Publication statusPublished - Aug 1 2018
Externally publishedYes


  • Fibrinolytic agents
  • Infusions, parenteral
  • ST elevation myocardial infarction
  • Therapeutics

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine


Dive into the research topics of 'Parenteral antithrombotic therapy during primary percutaneous coronary intervention'. Together they form a unique fingerprint.

Cite this